Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PACB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 3–5 Matrix Metrics)

PACB Overall Winner 6-Pillar Tally: NTLA 2 – 4 PACB Matrix Metrics: NTLA 5 – 3 PACB

As of Nov 16, 2026, Pacific Biosciences of California, Inc. (PACB) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.89 (N/M Forward P/E, -333.0% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. PACB 42.0/100 HOLD), PACB captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-333.0% vs. -826.0% operating margin) and revenue trajectory (+5.5% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs PACB
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86
PACB NASDAQ Head-to-Head Winner
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.27β · 112% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 15.0 Fund 36.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.4 · SMA20: $2.29 · SMA50: $2.02

6-Pillar Scorecard Institutional Category Breakdown (NTLA 2 – 4 PACB)

Columns: Metric · NTLA · PACB
1. Valuation Multiples PACB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x 7.8x
2. Growth & Scale PACB
Revenue Growth (YoY) -48.0% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $161M
Market Cap $1.5B $615.1M
3. Profitability & Quality PACB
Gross Margin N/A 27.7%
Operating Margin -826.0% -333.0%
Net Profit Margin 0.0% -81.3%
Return on Equity (ROE) -62.6% -929.3%
4. Balance Sheet & Cash Flow PACB
Cash Generation (TTM) -$358M -$150M
Cash Flow Margin N/A -93.2%
Net Cash / Leverage $74M Net Debt (0.38x D/E) $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NTLA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 92.6% (47th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.19x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (5) vs PACB (3)
Institutional Metric NTLA PACB Criterion Row Edge
Market Capitalization
Scale
$1.5B $615.1M Larger Scale NTLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% +5.5% Higher Growth PACB
Operating Margin (TTM)
Profitability
-826.0% -333.0% Higher Margin PACB
Net Profit Margin
Profitability
0.0% -81.3% Higher Margin NTLA
Return on Equity (ROE)
Capital Efficiency
-62.6% -929.3% Higher ROE NTLA
52-Week Range Position
Momentum
20% ($8–$18) 34% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 2.27β · 112% Vol Lower Realized Risk NTLA
Unified Institutional Score
Composite Signal
50.7 / 100 (HOLD) 42.0 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +21.39 pp
NTLA: -12.43% · PACB: +8.96%
3M Horizon PACB +79.14 pp
NTLA: -13.79% · PACB: +65.35%
6M Horizon PACB +85.11 pp
NTLA: -21.2% · PACB: +63.91%
1Y Horizon PACB +0.3 pp
NTLA: +15.34% · PACB: +15.64%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue PACB Revenue NTLA Op. Margin PACB Op. Margin Margin Leader
FY2018 $30M $80M -298.6% -128.4% PACB
FY2019 $40M $90M -246.8% -110.6% PACB
FY2020 $60M $80M -235.5% -132.3% PACB
FY2021 $30M $130M -810.4% -161.2% PACB
FY2022 $50M $130M -879.0% -239.4% PACB
FY2023 $40M $200M -1420.5% -166.8% PACB
FY2024 $60M $150M -923.1% -308.0% PACB
FY2025 $70M $160M -651.7% -346.2% PACB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 47th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs PACB Key Questions & Quantitative Answers

As of Nov 16, 2026, Pacific Biosciences of California, Inc. (PACB) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas PACB carries 42.0/100 (HOLD) at $1.89 (N/M Forward P/E, -333.0% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. PACB 42.0/100 HOLD), PACB captures the overall institutional head-to-head verdict (3–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-333.0% vs. -826.0% operating margin) and revenue trajectory (+5.5% vs. -48.0% YoY). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile PACB is in a Breakdown options structure phase (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

PACB screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.